e-Therapeutics signs two collaboration deals to enhance AI technology capabilities
Intellegens and Biorelate have AI tools, which can enhance e-Therapeutics’ existing computational network-driven drug discovery (NDD) technology. Intellegens is a spin-out from the University of Cambridge, which has developed an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.